FDA Approves Drug to Treat HER2-negative Breast Cancer with Germline BRCA Mutations

The U.S. Food and Drug Administration (FDA) has granted approval of talazoparib to treat adult patients with HER2-negative locally advanced or metastatic breast cancer with germline BRCA (gBRCA) mutations. 

Talazoparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, is marketed as Talzenna and distributed by Pfizer Inc. 

The decision follows the Phase 3 EMBRACA trial, an open-label, randomized study that compared talazoparib with chemotherapy in gBRCA locally advanced and/or metastatic breast cancer patients who have received no more than three previous chemotherapy regimens for advanced disease (n = 431). At a median 11.2 months follow-up, median progression-free survival in the talazoparib group was 8.6 months (95% CI, 7.2-9.3) compared to 5.6 months (95% CI, 4.2-6.7) in the chemotherapy group (HR, 0.54; 95% CI: 0.41-0.71; P < 0.0001). 

The FDA also approved the BRACAnalysis CDx test, a diagnostic companion that identifies patients with breast cancer with deleterious or suspected deleterious gBRCA mutations who are talazoparib candidates. The BRACAnalysis CDx test’s effectiveness was used during the EBRACA trial to determine if deleterious or suspected deleterious gBRCA mutations were present with either prospective or retrospective testing using the BRACAnalysis CDx test. The BRACAnalysis CDx test is manufactured by Myriad Genetic Laboratories, Inc. 

Talazoparib is to be taken in a once-daily single dose of 1 mg. The most common adverse effects associated with the drug were fatigue, anemia, nausea, neutropenia, headache, thrombocytopenia, vomiting, alopecia, diarrhea, and decreased appetite. 

Study Finds Mutant Genes Linked to Severe Breast Cancer 

Perception matters: Stressful life events increase breast cancer risk 

Weight Loss May Lower Breast Cancer Risk in Older Women 

Serglycin promotes breast cancer cell aggressiveness: Induction of epithelial to mesenchymal transition, proteolytic activity and IL-8 signaling 

Sources: FDAOncLive